A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.

PubWeight™: 2.78‹?› | Rank: Top 1%

🔗 View Article (PMID 2541335)

Published in N Engl J Med on May 25, 1989

Authors

H H Balfour1, B A Chace, J T Stapleton, R L Simmons, D S Fryd

Author Affiliations

1: Department of Laboratory Medicine, University of Minnesota Health Sciences Center, Minneapolis 55455.

Articles citing this

Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol (1998) 2.41

Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother (1991) 2.40

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother (1995) 1.91

Human herpesvirus 6. Clin Microbiol Rev (1997) 1.91

Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother (2004) 1.79

New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev (2000) 1.75

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev (1994) 1.54

Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol (1994) 1.52

Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 1.42

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother (1999) 1.38

OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant (1991) 1.11

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother (1994) 1.03

Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother (1993) 1.01

Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96

The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect (1995) 0.95

Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus. Antimicrob Agents Chemother (2002) 0.94

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation (1994) 0.93

Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s. Ann Surg (1991) 0.87

The mortality risk with graft function has decreased among children receiving a first kidney transplant in the United States. Kidney Int (2014) 0.86

Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients. J Urol (1992) 0.85

Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J Clin Microbiol (1994) 0.85

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother (1993) 0.84

Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients. Transplant Proc (1991) 0.82

Current status of renal transplantation. West J Med (1990) 0.81

Virus infections in bone marrow transplant recipients: a three year prospective study. J Clin Pathol (1990) 0.80

Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob Agents Chemother (2009) 0.80

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother (1991) 0.80

The impact of cytomegalovirus infection ≥1 year after primary renal transplantation. Clin Transplant (2010) 0.79

Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol (2003) 0.77

Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother (1993) 0.77

Infections after liver transplantation: risk factors and prevention. Transplant Proc (1991) 0.76

Polyradiculopathy and Gastroparesis due to Cytomegalovirus Infection in AIDS: A Case Report and Review of Literature. Am J Case Rep (2015) 0.75

Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506? Dig Dis Sci (1994) 0.75

Preventive antepartum care. Infect Dis Obstet Gynecol (1994) 0.75

A Systematic Review and Meta-analysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients. Int J Organ Transplant Med (2012) 0.75

A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients. Can J Infect Dis (1993) 0.75

An ounce of prevention - The new wave in HIV therapy. Can J Infect Dis (1992) 0.75

Acyclovir to prevent cytomegalovirus infection in renal-graft recipients. N Engl J Med (1989) 0.75

Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients. Transplant Proc (1995) 0.75

Articles by these authors

Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol (1975) 8.06

Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med (1987) 7.82

Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer (1979) 5.60

Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med (2001) 3.98

Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science (1992) 3.80

Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med (1992) 3.42

Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore) (1980) 3.42

Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A (1993) 3.24

Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg (1983) 3.15

Use of medical emergency team responses to reduce hospital cardiopulmonary arrests. Qual Saf Health Care (2004) 3.00

Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus. Gastroenterology (1999) 2.75

Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol (2000) 2.50

Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products of Kupffer cells. J Exp Med (1989) 2.49

Immunodepression after major surgery in normal patients. Surgery (1975) 2.48

Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A (1993) 2.46

Pancreatico-duodenal allotransplantation: experimental and clinical experience. Ann Surg (1970) 2.44

Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med (1982) 2.44

The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation (1987) 2.40

Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation (1985) 2.34

An L-arginine-dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro. J Exp Med (1989) 2.27

Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25

Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg (1991) 2.24

Proposed mechanisms for the translocation of intestinal bacteria. Rev Infect Dis (1988) 2.16

Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11

Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol (1991) 2.07

Chemiluminescence response of phagocytizing human monocytes. Infect Immun (1976) 2.01

Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg (1998) 2.00

Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA (1987) 1.84

Association of renal allograft rejection with virus infections. Am J Med (1974) 1.83

Pancreatic trauma: a review. Surgery (1972) 1.81

Antiserum to lymphocytes: prolonged survival of canine renal allografts. Science (1966) 1.81

Increased incidence of malignancy during chronic renal failure. Lancet (1975) 1.79

Chemiluminescence response of human leukocytes: influence of medium components on light production. Infect Immun (1977) 1.77

Family tension in the search for a kidney donor. JAMA (1971) 1.77

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA (1988) 1.76

Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol (1990) 1.76

Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg (1990) 1.74

Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A (1996) 1.71

Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet (1972) 1.71

Reactive nitrogen intermediates suppress the primary immunologic response to Listeria. J Immunol (1993) 1.69

Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents. Gastroenterology (2000) 1.69

Inducible cytosolic enzyme activity for the production of nitrogen oxides from L-arginine in hepatocytes. Biochem Biophys Res Commun (1990) 1.67

Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. Science (1976) 1.65

Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med (2006) 1.63

Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis (1993) 1.63

Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol (1994) 1.55

Effect of exogenous and endogenous nitric oxide on mitochondrial respiration of rat hepatocytes. Am J Physiol (1991) 1.54

Inhibition of chemotaxis Ng-monomethyl-L-arginine: a role for cyclic GMP. Blood (1989) 1.53

Hemorrhagic shock. Curr Probl Surg (1995) 1.53

The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery (1981) 1.53

Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol (1996) 1.53

Mechanisms of microbial synergy in polymicrobial surgical infections. Rev Infect Dis (1985) 1.51

Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood (1994) 1.49

Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis. FASEB J (1991) 1.48

In vitro assay to demonstrate high-level erythromycin resistance of a clinical isolate of Treponema pallidum. Antimicrob Agents Chemother (1988) 1.46

Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun (1987) 1.46

Evidence that rat Kupffer cells stimulate and inhibit hepatocyte protein synthesis in vitro by different mechanisms. Gastroenterology (1989) 1.45

Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery (1977) 1.45

Coagulation disorders in combat casualties. I. Acute changes after wounding. II. Effects of massive transfusion. 3. Post-resuscitative changes. Ann Surg (1969) 1.44

Use of medical emergency team (MET) responses to detect medical errors. Qual Saf Health Care (2004) 1.43

Steroid diabetes in renal transplant recipients: pathogenetic factors and prognosis. Surgery (1973) 1.43

Suppression of lipopolysaccharide-induced macrophage nitric oxide and cytokine production in vitro by a novel lipopolysaccharide antagonist. Surgery (1994) 1.42

Intra-abdominal infections in pancreas transplant recipients. Ann Surg (1986) 1.42

Thigh abscess. An uncommon presentation of intraabdominal sepsis. Am J Surg (1986) 1.41

Anatomic evidence for spontaneous closure of ventricular septal defect. Circulation (1966) 1.41

Hyperglycemic nonketotic coma after liver transplantation. Arch Surg (1972) 1.40

Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol (1993) 1.40

Uremic pericardial effusion. Treatment by catheter drainage and local nonabsorbable steroid administration. Nephron (1976) 1.39

Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg (1969) 1.37

Isolation of Chlamydia trachomatis from the lower respiratory tract of adults. Lancet (1980) 1.37

Cyclosporin A in renal transplantation: a prospective randomized trial. Surgery (1982) 1.36

Cure of dysgerminoma with widespread metastases appearing after renal transplantation. N Engl J Med (1970) 1.36

Role of resident macrophages, peripheral neutrophils, and translymphatic absorption in bacterial clearance from the peritoneal cavity. Infect Immun (1985) 1.35

Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann Surg (1974) 1.34

Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis (1991) 1.33

Pathologic anatomy of the lungs following shock and trauma. J Trauma (1968) 1.33

Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG. Science (1971) 1.33

Chemotactic deactivation of human neutrophils: evidence for nonspecific and specific components. Infect Immun (1978) 1.33

A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1 beta induces hepatic nitric oxide synthesis. J Immunol (1995) 1.33

Effect of neuraminidase on the stimulatory capacity of cells in human mixed lymphocyte cultures. Clin Exp Immunol (1971) 1.32

Acquired immunologic deficiencies after trauma and surgical procedures. Surg Gynecol Obstet (1974) 1.30

Immunogenicity and antigenicity of lymphoid cells treated with neuraminidase. Nat New Biol (1971) 1.29

Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J Virol (2000) 1.29

Prevention of urological complications after kidney transplantation. Ann Surg (1971) 1.29

Secondary bacterial peritonitis: the biologic basis of treatment. Curr Probl Surg (1979) 1.28

Renal transplantation in high-risk patients. Arch Surg (1971) 1.28

Chemotactic deactivation of human neutrophils: possible relationship to stimulation of oxidative metabolism. Infect Immun (1979) 1.27

Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg (1976) 1.26

Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting. Ann Surg (1984) 1.26

Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem (2000) 1.25

Renal transplantation in children ages 1 to 5 years. Pediatrics (1978) 1.25

Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive individuals prior to first thrush episode. J Clin Microbiol (2000) 1.25

Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J Leukoc Biol (1992) 1.25

Intestinal bacteria translocate into experimental intra-abdominal abscesses. Arch Surg (1986) 1.24

Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology (1985) 1.24

Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery (1980) 1.24

The clinical use of antilymphocyte globulin. N Engl J Med (1971) 1.24